// App-Quantinova.ai

PB1444 : LONG-TERM ANALYSES FROM L-MIND, A PHASE II STUDY OF TAFASITAMAB (MOR208) COMBINED WITH LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

Researchers

Presenter

  • Johannes Dll

Principal Investigators

  • Kami J Maddocks

  • Eva Gonzalez Barca

  • Wojciech Jurczak

  • Anna Marina Liberati

  • Ale Obr

  • Gianluca Gaidano

  • Pau Abrisqueta

  • Marc Andr

  • Martin Dreyling

  • Tobias Menne

  • Maren Dirnberger-Hertweck

  • Johannes Weirather

  • Sumeet Ambarkhane

  • Gilles Salles

Medical Centers

  • Department of Pediatrics, Palacky University and University Hospital, Olomouc, Czech Republic

  • Ludwig-Maximilians-University, University Hospital, Munich, Germany

  • Department of Hematology, Universite catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

  • Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon, France

  • Department of Hematology, Institut Catalá d’Oncologia (ICO), Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain

  • Department of Internal Medicine,Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center,Columbus, OH,United States

  • Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain

  • Division of Hematology, Department of Clinical and Experimental Medicine, Universita del Piemonte Orientale Amedeo Avogadro, Novara, Italy

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Freeman Hospital, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

  • Università degli Studi di Perugia,Azienda Ospedaliera Santa Maria di Terni,Terni,Italy

  • Department of Lung Cancer and Thoracic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

  • MorphoSys AG, Planegg, Germany

Locations

  • Czech Republic

  • Germany

  • Belgium

  • France

  • Spain

  • United States

  • Italy

  • United Kingdom

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Tafasitamab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02399085

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved